Stocktoria
Lexaria Bioscience Corp. LEXX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-10-28
Lexaria Bioscience Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 |
| R&D expense | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | -$5.7M |
| Income tax | — | — | — | $0 | $6,093 |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M |
| EPS (diluted) | $-0.66 | $-0.47 | $-1.01 | — | — |
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M |
| Free cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | — |
| Cash & equivalents | — | — | — | $5.8M | $10.9M |
| Inventory | — | — | $0 | $38,418 | $29,648 |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M |
| Total liabilities | $1.6M | $1.2M | $403,908 | $201,437 | $203,265 |
| Shareholders' equity | $3.0M | $8.0M | $3.0M | $7.9M | $13.1M |
Source: SEC EDGAR filings · CIK 0001348362 · as of 2025-08-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.